In silico prioritization of wighteone analogues as candidate EGFR L858R/T790M inhibitors
Journal of Chemical Research · 2026-11 · 50 (6)
DOI: 10.1177/17475198261507860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Research, online erschienen am 13.11.2026. Verfasst von Mwashi F. Misungwi und 2 weiteren Autor:innen. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer remains a major global health challenge, with epidermal growth factor receptor (EGFR) playing a key role in tumor progression and drug resistance, specifically in non-small cell lung cancer. In particular, the EGFR L858R/T790M mutation is strongly associated with resistance to tyrosine kinase inhibitors, highlighting the need for new inhibitory strategies. In this study, 400 wighteone analogues and the reference compound wighteone were computationally screened to prioritize candidates for potential interaction with EGFR L858R/T790M. Drug-likeness and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties were assessed using predictive models, which were then used to guide molecular docking and 200 ns molecular dynamics (MD) simulations to evaluate binding affinity and complex stability. Nine analogues and the reference compound met the predefined physicochemical and predicted pharmacokinetic criteria, whereas CHEMBL491480 was excluded because of its predicted acute toxicity. Docking calculations yielded more favorable scores for CHEMBL238844 (−9.7 kcal/mol) and CHEMBL253043 (−9.3 kcal/mol) than for wighteone (-8.4 kcal/mol); these values were used for relative prioritization rather than as direct measures of biological potency. During the 200 ns MD simulations, the CHEMBL253043-EGFR L858R/T790M complex showed the lowest average RMSD (0.170 ± 0.032 nm) among the ligand-bound systems examined, together with a compact radius of gyration (2.026 ± 0.012 nm) and a solvent-accessible surface area of 158.357 ± 3.122 nm 2 . In addition, free energy landscape analysis confirmed a well-defined low-energy basin for CHEMBL253043, which further supports its enhanced conformational stability. Notably, MM/PBSA binding free energy analysis showed that CHEMBL253043 exhibits the most favorable binding energy (−88.266 ± 2.900 kJ/mol), compared with CHEMBL238844 (−74.734 ± 3.112 kJ/mol) and wighteone (−83.375 ± 3.068 kJ/mol), confirming its superior thermodynamic stability within the EGFR L858R/T790M binding pocket. Collectively, these computational results prioritize CHEMBL253043 for subsequent experimental investigation; they do not establish EGFR inhibition, anticancer activity, pharmacokinetic suitability, therapeutic efficacy, or superiority over clinically approved EGFR inhibitors.
Zitieren
APA
Misungwi, M. F., Paul, L., & Mlowe, S. (2026). In silico prioritization of wighteone analogues as candidate EGFR L858R/T790M inhibitors. Journal of Chemical Research, 50(6). https://doi.org/10.1177/17475198261507860
Vancouver
Misungwi MF, Paul L, Mlowe S. In silico prioritization of wighteone analogues as candidate EGFR L858R/T790M inhibitors. Journal of Chemical Research. 2026;50(6). doi:10.1177/17475198261507860
BibTeX
@article{Misungwi2026,
author = {Misungwi, Mwashi F. and Paul, Lucas and Mlowe, Sixberth},
title = {In silico prioritization of wighteone analogues as candidate EGFR L858R/T790M inhibitors},
journal = {Journal of Chemical Research},
year = {2026},
volume = {50},
number = {6},
doi = {10.1177/17475198261507860}
}
EUVIMED